Abstract:Corporate management is often accused of short-term oriented behaviour related to R&D expenditures. This study analyses the influence of R&D volatility and R&D intensity on the market capitalization of pharmaceutical and medical research companies from Europe, considering the institutional context and several firm characteristics. Panel regression estimations on a sample of 217 companies for 2014–2019 indicate that R&D volatility adversely affects market value. The analysis is conducted on the entire sample and on sub-samples determined based on the positive and negative values of the R&D volatility. This differentiates between the continuous and the disrupting effect of R&D activities and the firm's shift between exploratory and exploitative innovations. The positive volatility sub-sample provides consistent evidence of a significant negative influence of the R&D volatility on the market value. For the negative volatility sub-sample, R&D intensity and its interaction with R&D volatility have a significant positive effect, consistent over the alternative estimations. We conclude that the market influence of the R&D expenditure is related to the sign of volatility and depends on the proportion of R&D expenditure, especially when the volatility is negative. Our findings provide valuable insights for managers, investors, analysts, and other stakeholders about the market reaction to R&D volatility.

Corporate R&D Investments Following Competitors’ Voluntary Disclosures: Evidence from the Drug Development Process

The Spillover Effects of Innovation Content Disclosure in MD&A

Corporate Innovation and R&D Expenditure Disclosures

Peer Competitive Threats, Common Customers, and Strategic News Disclosure

Peer Effects of Corporate Disclosures: Evidence From the Registration-Based IPO System in China

Uncertainty and Corporate R&D Investment: Evidence from Chinese Listed Firms

Peer Effects in Corporate Disclosure Decisions

Knowledge Spillovers and Corporate Investment in Scientific Research

Peer effects in government R&D subsidies: evidence from the awareness-motivation-capability perspective

Peer effects of corporate product quality information disclosure: Learning and competition

R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry

Public Funding for Science and the Value of Corporate R&D Projects; Evidence from Project Initiation and Termination Decisions in Cell Therapy

Does R&D make stocks lottery-like?

Comparison of R&D information disclosure of Chinese and foreign listed pharmaceutical enterprises – Take Hengrui Pharmaceutical and Pfizer Pharmaceutical as examples

Corporate Science, Innovation and Firm Value

Financial Market Reaction To R&D Volatility In The Pharmaceutical Industry. A Multi-Country Study

Who leads and who follows? The cross-border peer effect in investment by Chinese and US firms

Peer Effects and Disclosure Timing: Evidence from Earnings Announcements

The Peer Effects on Disclosure of Corporate Internal Control Weakness

R&D investment and distress risk